Congrats to Rony for his paper published today in Embo Mol Medicine

This study (https://www.embopress.org/doi/10.15252/emmm.202113977) reports a FZD4:LRP5 antibody agonist (F4L5.13) that activates βcatenin signaling in endothelial cells. F4L5.13 shows efficacy in animal models by normalizing defective retinal angiogenesis and barrier function, providing a novel therapeutic strategy for eye diseases.

• βcatenin signaling was activated by F4L5.13, which functions as a Norrin surrogate in endothelial cells.
• Endothelial barrier function was promoted, and VEGF-induced endothelial permeability was blocked by F4L5.13.
• Retinal barrier function was restored by F4L5.13 in Tspan12^−/− mice.
• Pathological neovascularization was reduced by F4L5.13 in an OIR model.
•